C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Φόρτωση...
Ημερομηνία
Συγγραφείς
Lengyel, E.
Prechtel, D.
Resau, J. H.
Gauger, K.
Welk, A.
Lindemann, K.
Salanti, G.
Richter, T.
Knudsen, B.
Vande Woude, G. F.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Int J Cancer
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression. Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease-free survival in patients with c-Met overexpressing tumors was 8 months compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Aged, 80 and over, Breast Neoplasms/drug therapy/*metabolism/*pathology, Disease Progression, Disease-Free Survival, Female, Fibrocystic Breast Disease/drug therapy/metabolism/pathology, Hepatocyte Growth Factor/metabolism, Humans, Hyperplasia/drug therapy/metabolism/pathology, Ligands, Lymph Nodes/pathology, Lymphatic Metastasis/*pathology, Middle Aged, Neoplasm Staging, Pilot Projects, Proto-Oncogene Proteins c-met/*metabolism, Receptor, erbB-2/*metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism, Risk Factors, Survival Rate, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/15455388
http://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f
http://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής